AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
AAPL   373.85 (+2.68%)
MSFT   210.70 (+2.15%)
FB   240.28 (+2.94%)
GOOGL   1,499.65 (+2.02%)
AMZN   3,057.04 (+5.77%)
NVDA   393.57 (+2.36%)
CGC   16.94 (+2.98%)
BABA   240.00 (+7.33%)
MU   50.92 (+2.19%)
GE   7.00 (+2.64%)
TSLA   1,371.58 (+13.48%)
AMD   53.40 (+2.03%)
T   30.49 (+1.36%)
ACB   12.18 (-0.73%)
F   6.19 (+2.31%)
GILD   76.76 (+0.54%)
DIS   114.43 (+2.01%)
BAC   23.66 (+1.59%)
NFLX   493.81 (+3.55%)
BA   187.91 (+3.93%)
Log in

NASDAQ:SYRSSyros Pharmaceuticals Competitors & Alternatives

$11.47
-0.68 (-5.60 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$11.35
Now: $11.47
$12.39
50-Day Range
$8.60
MA: $9.88
$12.15
52-Week Range
$4.26
Now: $11.47
$12.39
Volume349,905 shs
Average Volume314,946 shs
Market Capitalization$524.10 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

Syros Pharmaceuticals (NASDAQ:SYRS) Vs. IGMS, PCRX, QURE, CORT, EIDX, and DRNA

Should you be buying SYRS stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Syros Pharmaceuticals, including IGM Biosciences (IGMS), Pacira Biosciences (PCRX), Uniqure (QURE), Corcept Therapeutics (CORT), Eidos Therapeutics (EIDX), and Dicerna Pharmaceuticals (DRNA).

Syros Pharmaceuticals (NASDAQ:SYRS) and IGM Biosciences (NASDAQ:IGMS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Syros Pharmaceuticals and IGM Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%
IGM BiosciencesN/AN/AN/A

Valuation & Earnings

This table compares Syros Pharmaceuticals and IGM Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10
IGM BiosciencesN/AN/A$-43,130,000.00($4.80)-14.75

IGM Biosciences has lower revenue, but higher earnings than Syros Pharmaceuticals. IGM Biosciences is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Syros Pharmaceuticals and IGM Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syros Pharmaceuticals02502.71
IGM Biosciences00903.00

Syros Pharmaceuticals presently has a consensus price target of $13.2857, indicating a potential upside of 15.83%. IGM Biosciences has a consensus price target of $65.4286, indicating a potential downside of 7.61%. Given Syros Pharmaceuticals' higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than IGM Biosciences.

Insider & Institutional Ownership

98.2% of Syros Pharmaceuticals shares are owned by institutional investors. Comparatively, 43.3% of IGM Biosciences shares are owned by institutional investors. 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 79.3% of IGM Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

IGM Biosciences beats Syros Pharmaceuticals on 7 of the 12 factors compared between the two stocks.

Syros Pharmaceuticals (NASDAQ:SYRS) and Pacira Biosciences (NASDAQ:PCRX) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations and institutional ownership.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Syros Pharmaceuticals and Pacira Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Syros Pharmaceuticals02502.71
Pacira Biosciences051002.67

Syros Pharmaceuticals presently has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Pacira Biosciences has a consensus price target of $58.1429, indicating a potential upside of 11.02%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe Syros Pharmaceuticals is more favorable than Pacira Biosciences.

Insider & Institutional Ownership

98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Comparatively, 6.2% of Pacira Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares Syros Pharmaceuticals and Pacira Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%
Pacira Biosciences-0.02%13.89%6.06%

Volatility & Risk

Syros Pharmaceuticals has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Pacira Biosciences has a beta of 1.31, suggesting that its stock price is 31% more volatile than the S&P 500.

Valuation & Earnings

This table compares Syros Pharmaceuticals and Pacira Biosciences' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10
Pacira Biosciences$421.03 million5.24$-11,020,000.00$0.8660.90

Pacira Biosciences has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Pacira Biosciences, indicating that it is currently the more affordable of the two stocks.

Uniqure (NASDAQ:QURE) and Syros Pharmaceuticals (NASDAQ:SYRS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Uniqure and Syros Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Uniqure041002.71
Syros Pharmaceuticals02502.71

Uniqure presently has a consensus price target of $75.8333, indicating a potential upside of 69.23%. Syros Pharmaceuticals has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Given Uniqure's higher possible upside, equities analysts plainly believe Uniqure is more favorable than Syros Pharmaceuticals.

Insider and Institutional Ownership

78.7% of Uniqure shares are owned by institutional investors. Comparatively, 98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 2.7% of Uniqure shares are owned by company insiders. Comparatively, 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Uniqure and Syros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Uniqure-1,991.17%-45.23%-31.35%
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%

Risk and Volatility

Uniqure has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Earnings and Valuation

This table compares Uniqure and Syros Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Uniqure$7.28 million272.76$-124,200,000.00($3.11)-14.41
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10

Syros Pharmaceuticals has lower revenue, but higher earnings than Uniqure. Uniqure is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Syros Pharmaceuticals beats Uniqure on 7 of the 13 factors compared between the two stocks.

Corcept Therapeutics (NASDAQ:CORT) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Corcept Therapeutics and Syros Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Corcept Therapeutics01202.67
Syros Pharmaceuticals02502.71

Corcept Therapeutics presently has a consensus price target of $17.6667, indicating a potential upside of 5.66%. Syros Pharmaceuticals has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Given Syros Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Syros Pharmaceuticals is more favorable than Corcept Therapeutics.

Insider and Institutional Ownership

76.2% of Corcept Therapeutics shares are owned by institutional investors. Comparatively, 98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 15.5% of Corcept Therapeutics shares are owned by company insiders. Comparatively, 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Corcept Therapeutics and Syros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Corcept Therapeutics31.64%30.00%27.29%
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%

Risk and Volatility

Corcept Therapeutics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Earnings and Valuation

This table compares Corcept Therapeutics and Syros Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Corcept Therapeutics$306.49 million6.25$94.18 million$0.7721.71
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10

Corcept Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Syros Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Summary

Corcept Therapeutics beats Syros Pharmaceuticals on 8 of the 14 factors compared between the two stocks.

Eidos Therapeutics (NASDAQ:EIDX) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Eidos Therapeutics and Syros Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eidos Therapeutics12702.60
Syros Pharmaceuticals02502.71

Eidos Therapeutics presently has a consensus price target of $57.80, indicating a potential upside of 17.31%. Syros Pharmaceuticals has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Given Eidos Therapeutics' higher possible upside, equities analysts plainly believe Eidos Therapeutics is more favorable than Syros Pharmaceuticals.

Insider and Institutional Ownership

32.1% of Eidos Therapeutics shares are owned by institutional investors. Comparatively, 98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 71.6% of Eidos Therapeutics shares are owned by company insiders. Comparatively, 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Eidos Therapeutics and Syros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Eidos TherapeuticsN/A-30.48%-26.79%
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%

Risk and Volatility

Eidos Therapeutics has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Earnings and Valuation

This table compares Eidos Therapeutics and Syros Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Eidos Therapeutics$26.69 million71.14$-37,830,000.00($1.03)-47.83
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10

Eidos Therapeutics has higher revenue and earnings than Syros Pharmaceuticals. Eidos Therapeutics is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Eidos Therapeutics beats Syros Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Dicerna Pharmaceuticals (NASDAQ:DRNA) and Syros Pharmaceuticals (NASDAQ:SYRS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations and institutional ownership.

Analyst Ratings

This is a summary of current recommendations for Dicerna Pharmaceuticals and Syros Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Dicerna Pharmaceuticals001103.00
Syros Pharmaceuticals02502.71

Dicerna Pharmaceuticals presently has a consensus price target of $34.20, indicating a potential upside of 32.66%. Syros Pharmaceuticals has a consensus price target of $13.2857, indicating a potential upside of 15.83%. Given Dicerna Pharmaceuticals' stronger consensus rating and higher possible upside, equities analysts plainly believe Dicerna Pharmaceuticals is more favorable than Syros Pharmaceuticals.

Risk and Volatility

Dicerna Pharmaceuticals has a beta of 1.82, suggesting that its share price is 82% more volatile than the S&P 500. Comparatively, Syros Pharmaceuticals has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500.

Insider and Institutional Ownership

82.8% of Dicerna Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.2% of Syros Pharmaceuticals shares are owned by institutional investors. 11.3% of Dicerna Pharmaceuticals shares are owned by company insiders. Comparatively, 14.2% of Syros Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Profitability

This table compares Dicerna Pharmaceuticals and Syros Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Dicerna Pharmaceuticals-213.04%-74.79%-22.53%
Syros Pharmaceuticals-1,950.42%-84.15%-50.21%

Earnings and Valuation

This table compares Dicerna Pharmaceuticals and Syros Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Dicerna Pharmaceuticals$23.90 million79.73$-120,460,000.00($1.76)-14.65
Syros Pharmaceuticals$1.98 million264.70$-75,440,000.00($1.88)-6.10

Syros Pharmaceuticals has lower revenue, but higher earnings than Dicerna Pharmaceuticals. Dicerna Pharmaceuticals is trading at a lower price-to-earnings ratio than Syros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Dicerna Pharmaceuticals beats Syros Pharmaceuticals on 9 of the 14 factors compared between the two stocks.

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
IGMS
IGM Biosciences
1.5$70.82-2.2%$2.21 billionN/A-14.75
Pacira Biosciences logo
PCRX
Pacira Biosciences
1.6$52.37-1.5%$2.21 billion$421.03 million-2,617.19Analyst Report
Heavy News Reporting
Uniqure logo
QURE
Uniqure
1.7$44.81-1.6%$2.02 billion$7.28 million-14.89Analyst Revision
Corcept Therapeutics logo
CORT
Corcept Therapeutics
1.1$16.72-2.8%$1.91 billion$306.49 million19.00Heavy News Reporting
Eidos Therapeutics logo
EIDX
Eidos Therapeutics
1.1$49.27-2.5%$1.90 billion$26.69 million-37.33Heavy News Reporting
Dicerna Pharmaceuticals logo
DRNA
Dicerna Pharmaceuticals
1.7$25.78-0.4%$1.90 billion$23.90 million-15.25Decrease in Short Interest
Xencor logo
XNCR
Xencor
1.4$32.82-2.7%$1.87 billion$156.70 million-30.67
Principia Biopharma logo
PRNB
Principia Biopharma
1.4$57.29-2.3%$1.85 billion$35.16 million-23.48Analyst Report
Insider Selling
Heavy News Reporting
Myovant Sciences logo
MYOV
Myovant Sciences
1.9$20.03-0.6%$1.82 billionN/A-5.94
Prestige Consumer Healthcare logo
PBH
Prestige Consumer Healthcare
1.8$36.28-0.3%$1.82 billion$963.01 million13.05Increase in Short Interest
Ligand Pharmaceuticals logo
LGND
Ligand Pharmaceuticals
1.4$113.82-1.9%$1.79 billion$120.28 million-33.09
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.8$15.48-0.5%$1.75 billion$320,000.00-11.82
Madrigal Pharmaceuticals logo
MDGL
Madrigal Pharmaceuticals
1.8$109.37-2.0%$1.72 billionN/A-16.06
ZNTL
Passage Bio
1.7$47.97-0.4%$1.72 billionN/A0.00Analyst Downgrade
Akebia Therapeutics logo
AKBA
Akebia Therapeutics
1.5$13.07-0.2%$1.70 billion$335 million-5.91
IMAB
I-Mab
1.2$29.32-1.0%$1.67 billion$4.31 million-1.01
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.3$42.66-1.7%$1.67 billionN/A-17.13Heavy News Reporting
Zymeworks logo
ZYME
Zymeworks
1.7$37.12-3.1%$1.64 billion$29.54 million-9.54Increase in Short Interest
Ironwood Pharmaceuticals logo
IRWD
Ironwood Pharmaceuticals
1.6$10.18-0.1%$1.62 billion$428.41 million19.21Analyst Downgrade
Zogenix logo
ZGNX
Zogenix
2.0$29.19-0.4%$1.62 billion$3.65 million-3.09
Intra-Cellular Therapies logo
ITCI
Intra-Cellular Therapies
1.5$23.55-2.8%$1.60 billion$60,000.00-8.47
Epizyme logo
EPZM
Epizyme
1.6$15.81-0.1%$1.60 billion$23.80 million-7.79
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.8$46.10-2.1%$1.59 billion$252 million-4.30High Trading Volume
Analyst Revision
Cytokinetics logo
CYTK
Cytokinetics
1.4$24.35-2.0%$1.48 billion$26.87 million-10.87Decrease in Short Interest
Analyst Revision
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.8$19.57-0.7%$1.46 billion$40.89 million-6.70
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
2.0$22.21-0.5%$1.44 billion$42.12 million-15.86
Revance Therapeutics logo
RVNC
Revance Therapeutics
1.1$26.18-4.0%$1.43 billion$410,000.00-6.61Analyst Downgrade
Akcea Therapeutics logo
AKCA
Akcea Therapeutics
1.2$14.13-1.6%$1.43 billion$488.54 million-47.10
ZEALAND PHARMA/S logo
ZEAL
ZEALAND PHARMA/S
1.0$35.85-3.0%$1.42 billion$6.20 million-13.28Analyst Downgrade
MacroGenics logo
MGNX
MacroGenics
1.3$28.87-2.2%$1.42 billion$64.19 million-9.34Increase in Short Interest
Portola Pharmaceuticals logo
PTLA
Portola Pharmaceuticals
1.5$18.03-0.0%$1.41 billion$116.64 million-4.78Heavy News Reporting
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.4$23.05-3.0%$1.41 billionN/A-10.34Analyst Downgrade
Innoviva logo
INVA
Innoviva
0.9$13.80-1.4%$1.41 billion$261.02 million8.07
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.6$14.97-3.7%$1.40 billion$145.97 million-6.59Analyst Revision
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.4$50.96-0.3%$1.40 billion$148.36 million-5.29Increase in Short Interest
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$4.52-2.7%$1.35 billion$1.63 billion-2.81
ARVN
Arvinas
1.6$33.88-0.8%$1.33 billion$42.98 million-15.33Increase in Short Interest
Tricida logo
TCDA
Tricida
1.8$26.49-1.1%$1.32 billionN/A-6.16Increase in Short Interest
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.5$20.52-0.7%$1.29 billion$73.41 million-4.73Increase in Short Interest
Odonate Therapeutics logo
ODT
Odonate Therapeutics
1.0$40.12-6.0%$1.29 billionN/A-10.21
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.8$23.58-0.1%$1.25 billion$392.76 million10.87
Rocket Pharmaceuticals logo
RCKT
Rocket Pharmaceuticals
1.8$22.41-0.6%$1.24 billionN/A-14.01
ARQT
I-Mab
1.5$32.28-0.8%$1.22 billionN/A0.00
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$28.91-0.2%$1.22 billionN/A-9.90
Athenex logo
ATNX
Athenex
2.1$13.65-0.5%$1.12 billion$101.23 million-9.68
Arcus Biosciences logo
RCUS
Arcus Biosciences
1.7$24.03-0.1%$1.11 billion$15 million-11.13Increase in Short Interest
Analyst Revision
Aimmune Therapeutics logo
AIMT
Aimmune Therapeutics
1.6$17.36-3.1%$1.10 billionN/A-3.91Analyst Revision
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$26.28-0.8%$1.05 billion$828 million29.20
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.3$48.03-8.6%$1.05 billionN/A-20.44Increase in Short Interest
Heavy News Reporting
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.5$21.92-1.4%$1.01 billion$322.36 million20.88
This page was last updated on 7/6/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.